Delivering precision oncology to patients with cancer
Delivering precision oncology to patients with cancer
复制标题
DOI：
10.1038/s41591-022-01717-2
复制
发表时间：
2022-04-01
期刊：
影响因子：
82.9
通讯作者：
Voest, Emile
中科院分区：
文献类型：
--
作者：
Mateo, Joaquin;Steuten, Lotte;Voest, Emile
精准医疗正在重塑癌症护理，但并不是所有患者都能享受到好处。这一视角概述了实施精确肿瘤学的主要挑战，并讨论了解决这些挑战的关键步骤。随着基因组图谱在许多肿瘤类型中越来越多地用于诊断和治疗指导，精确肿瘤学正在迅速重塑癌症护理。然而，目前肿瘤学药物开发的轨迹导致了一个悖论：如果患者无法获得先进的诊断方法，我们可能正在开发能够接触到少数患者的药物。在这一视角下，我们概述了实施精确肿瘤学面临的主要挑战，并讨论了解决这些挑战的关键步骤，包括促进平等获得基因组测试，确保临床研究为新药和技术提供强有力的证据，使医生能够解释基因组数据，以及增强患者的共享决策能力。为了将精确肿瘤学的进步转化为全球癌症患者的利益，有必要采取多方利益相关者的方法来生成证据、评估价值和提供医疗保健。
Precision medicine is reshaping cancer care, but the benefits are not accessible to all patients. This Perspective outlines the major challenges to the implementation of precision oncology and discusses critical steps toward resolving these.With the increasing use of genomic profiling for diagnosis and therapy guidance in many tumor types, precision oncology is rapidly reshaping cancer care. However, the current trajectory of drug development in oncology results in a paradox: if patients cannot access advanced diagnostics, we may be developing drugs that will reach few patients. In this Perspective, we outline the major challenges to the implementation of precision oncology and discuss critical steps toward resolving these, including facilitation of equal access to genomics tests, ensuring that clinical studies provide robust evidence for new drugs and technologies, enabling physicians to interpret genomics data, and empowering patients toward shared decision-making. A multi-stakeholder approach to evidence generation, value assessment, and healthcare delivery is necessary to translate advances in precision oncology into benefits for patients with cancer globally.